已收盘 01-30 16:00:00 美东时间
-0.110
-0.54%
BUZZ-Velocity Financial jumps after Q4 preliminary results ** Shares of lender Velocity Financial VEL.N rise 7.22% to $20.79 after Q4 preliminary unaudited results ** Co expects net income of at least $35 million, an increase of at least 70% ** Separately, co announced $500 million of senior notes d
01-27 04:20
Velocity Financial's prelim Q4 profit rises 70% on higher loan originations Overview Real estate loan provider's preliminary Q4 net income rises 70% yr/yr Preliminary Q4 EPS grows 56% yr/yr Company's preliminary Q4 loan originations increase 13% yr/yr Outlook Velocity Financial plans to leverage 202
01-26 21:39
Velocity Financial Inc. Q4 net income at least USD 35 million, up over 70% Velocity Financial Inc. announced preliminary unaudited results for the fourth quarter and full year 2025. For the fourth quarter (Q4), net income was at least USD 35 million, an increase of at least 70%. GAAP earnings per di
01-26 21:35
Velocity Financial Launches $500 Million Senior Notes Offering Velocity Financial, Inc. has announced a proposed offering of up to $500 million in Senior Notes due 2031. The notes will be issued by Velocity Commercial Capital, LLC, a wholly-owned subsidiary of the company, and offered to qualified i
01-26 21:31
BRIEF-Velocity Financial Q4 Net Income USD 35 Million Jan 26 (Reuters) - Velocity Financial Q4 EPS USD 0.9.
01-26 21:30
Velocity Financial Expects Record 2025 Net Income and Loan Originations Velocity Financial Inc. has announced its preliminary unaudited financial expectations for the fourth quarter and full year of 2025. For the three months ended December 31, 2025, the company expects net income of at least $35 mi
01-26 21:30
Velocity Financial ( ($VEL) ) has issued an update. On December 16, 2025, Veloc...
2025-12-17 01:58
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从4美元升至9美元;BTIG:维持Cullinan Therapeutics"买入"评级,目标价从32美元升至38美元
2025-11-25 10:27
BTIG analyst Eric Hagen reiterates Velocity Financial (NYSE:VEL) with a Buy and maintains $23 price target.
2025-11-24 18:32
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17